Postpartum Depression: Pathophysiology, Treatment, and Emerging Therapeutics.

  title={Postpartum Depression: Pathophysiology, Treatment, and Emerging Therapeutics.},
  author={Donna Eileen Stewart and Simone N. Vigod},
  journal={Annual review of medicine},
  • D. Stewart, S. Vigod
  • Published 28 January 2019
  • Psychology, Medicine
  • Annual review of medicine
Postpartum depression (PPD) is common, disabling, and treatable. The strongest risk factor is a history of mood or anxiety disorder, especially having active symptoms during pregnancy. As PPD is one of the most common complications of childbirth, it is vital to identify best treatments for optimal maternal, infant, and family outcomes. New understanding of PPD pathophysiology and emerging therapeutics offer the potential for new ways to add to current medications, somatic treatments, and… 
Postpartum Depression: A Nurse's Guide.
Initial information about PPD is provided, reviewing the risk factors for and the consequences of this mood disorder, and screening and treatment options are explained.
Oxytocin and postpartum depression - a possible treatment for depressed mothers
Oxytocin plays an undeniable role in pathophysiology of postpartum depression and it may be regarded as a diagnostic indicator and therapeutic target, however, more studies are needed to clarify this intricate relationship.
Agomelatine for postpartum depression and breastfeeding
  • Le Xiao
  • Medicine, Psychology
    Therapeutic advances in psychopharmacology
  • 2021
The short half-life of agomelatine was taken advantage to reduce the potential effect on infant in the treatment of a nursing woman with PPD and demonstrate the safety in breastfeeding.
Review Article Brexanolone: A Pharmacotherapy Approach in Post Partum Depression
Postpartum depression is characterized by feelings of sadness, worthlessness or guilt, cognitive impairment, and/or possibly suicidal ideation, it is considered as a life-threatening condition in
The Effects of Ibuprofen Consumption on the Incidence of Postpartum Depression
A prospective observational trial examining whether consumption of higher doses of the nonsteroidal anti-inflammatory drug ibuprofen is associated with a lower incidence of postpartum depression found that ib uprofen consumption was significantlyassociated with a reduced risk of development of PPD at week 3 among high-risk women not taking psychotropic medications.
Treating Postpartum Depression: What Do We Know about Brexanolone?
The pharmacology of brexanolone is reviewed, the latest available clinical data and outcomes concerning its use are evaluated, its position as a ‘breakthrough’ in managing PPD is reevaluate, and the cost-related barriers to its worldwide standardized use are reviewed.
Antidepressant treatment for postnatal depression.
Low-certainty evidence is found that SSRI antidepressants may be more effective in treating postnatal depression than placebo as measured by response and remission rates.
Postpartum hemorrhage and postpartum depressive symptoms: A retrospective cohort study
PPH may increase the risk of postpartum depressive symptoms, and women with PPH should be actively screened for depressive symptoms in the immediate post partum period.